(Q33385560)

26 July 2017

1 reference

title

Heparin-induced thrombocytopenia: a renal perspective (English)

1 reference

heparin-induced thrombocytopenia

26 July 2017

1 reference

1 reference

Samaha Syed

1

1 reference

26 July 2017

Robert F Reilly

series ordinal

2

1 reference

26 July 2017

language of work or name

English

0 references

publication date

28 July 2009

1 reference

Nature Reviews Nephrology

26 July 2017

published in

1 reference

26 July 2017

volume

5

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

501-511

1 reference

Arterial Embolism Occurring During Systemic Heparin Therapy

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

When heparin causes thrombosis: significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Delayed-onset heparin-induced thrombocytopenia and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

21 January 2018

12 December 2020

Heparin induced thrombocytopenia: diagnosis and management update

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

The pathophysiology of immune-mediated heparin-induced thrombocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

A case review: anticoagulation in hemodialysis patients with heparin-induced thrombocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Heparin-induced thrombocytopenia: a historical perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

A 14-year study of heparin-induced thrombocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Letter: Heparin: adverse reaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Sudden collapse during haemodialysis due to immune-mediated heparin-induced thrombocytopaenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Immune endothelial-cell injury in heparin-associated thrombocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Heparin-induced thrombocytopenia: some working hypotheses on pathogenesis, diagnostic strategies and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

What is the potential for overdiagnosis of heparin-induced thrombocytopenia?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Heparin-induced thrombocytopenia in hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

The presence of heparin-platelet factor 4 antibodies as a marker of hypercoagulability during hemodialysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Treatment of midgestational placental haemorrhage with recombinant factor VIIa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Anti-PF4/heparin antibodies associated with repeated hemofiltration-filter clotting: a retrospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Heparin-induced thrombocytopenia: a possible complication of heparin-coated pulmonary artery catheters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Heparin induced thrombocytopaenia secondary to intraperitoneal heparin exposure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Pharmacology of r-hirudin in renal impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

The management of heparin-induced thrombocytopenia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

The approach to heparin-induced thrombocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Excessive anticoagulation and anaphylactic reaction after rechallenge with lepirudin in a patient with heparin-induced thrombocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Quantitative determination of hirudin in blood and body fluids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Direct thrombin inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Argatroban for anticoagulation in continuous renal replacement therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Argatroban anticoagulation in renal dysfunction: a literature analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Heparin-induced thrombocytopenia: treatment options and special considerations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

HIT on dialysis--when is it safe to re-challenge?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.125

Arterial embolism occurring during systemic heparin therapy

31 March 2020

1 reference

12 December 2020

Heparin-induced thrombocytopenia: towards consensus.

1 reference

12 December 2020

Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4.

1 reference

12 December 2020

Heparin-induced antibodies and cardiovascular risk in patients on dialysis

1 reference

12 December 2020

Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialysis

1 reference

12 December 2020

Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.

1 reference

12 December 2020

Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.

1 reference

12 December 2020

Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations

1 reference

12 December 2020

The presence of antibodies against a PF4-heparin complex in patients on haemodialysis

1 reference

12 December 2020

Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes.

1 reference

12 December 2020

Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.

1 reference

12 December 2020

Treatment of hirudin overdosage in a patient with chronic renal failure

1 reference

12 December 2020

Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2009.125

1 reference

Dimensions Publication ID

26 July 2017

1034381493

0 references

1 reference